STOCK TITAN

SINTX Technologies Announces Closing of $8.2 Million Registered Direct Offering

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

SINTX Technologies, Inc. (NASDAQ: SINT) announced the closing of a registered direct offering of 3,415,000 shares at $2.40 per share, raising gross proceeds of $8.2 million. The shares were offered under a previously filed shelf registration statement. Maxim Group LLC served as the sole placement agent. The proceeds will be allocated for general working capital and corporate purposes. SINTX specializes in the production of silicon nitride ceramics for medical applications, with its manufacturing facility FDA registered and ISO certified.

Positive
  • Raised $8.2 million through a direct offering.
  • Proceeds will support general working capital and corporate purposes.
  • SINTX's facility is FDA registered and ISO 13485:2016 certified.
Negative
  • Offering may lead to shareholder dilution.
  • No detailed plans provided on how raised funds will be utilized.

SALT LAKE CITY, UT , Aug. 10, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications announced the closing of its previously announced registered direct offering of 3,415,000 shares of its common stock at a purchase price of $2.40 per share for gross proceeds of $8.2 million priced at-the-market under Nasdaq rules.

The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-230492) previously filed and declared effective by the Securities and Exchange Commission (SEC) on April 5, 2019. The offering of the shares of common stock was made by means of prospectus supplements that were filed with the SEC and form a part of the registration statement.

Maxim Group LLC acted as the sole placement agent for the offering. SINTX intends to use the net proceeds from the offerings for general working capital and general corporate purposes.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock was filed by SINTX with the SEC. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

About SINTX Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company manufactures silicon nitride material and components in its FDA registered and ISO 13485:2016 certified facility.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things, that future studies may not confirm the antiviral properties of silicon nitride; that application of silicon nitride to products may not result in products with antiviral properties; uncertainties inherent in research and development, including the cost and time required advance our products to regulatory submission; market acceptance of our products once cleared and commercialized; our ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Contact:
SINTX Technologies
801.839.3502
IR@sintx.com


FAQ

What is SINTX's recent stock offering details?

SINTX closed a registered direct offering of 3,415,000 shares at $2.40 per share, raising $8.2 million.

Who acted as the placement agent for SINTX's stock offering?

Maxim Group LLC was the sole placement agent for the offering.

How does SINTX plan to use the proceeds from the offering?

The proceeds will be used for general working capital and corporate purposes.

What is the significance of SINTX's facility certification?

SINTX's facility is FDA registered and ISO 13485:2016 certified, ensuring compliance in manufacturing.

Is there any risk related to the recent stock offering?

Yes, the offering could potentially lead to shareholder dilution.

SiNtx Technologies, Inc.

NASDAQ:SINT

SINT Rankings

SINT Latest News

SINT Stock Data

1.61M
750.00k
3.01%
1.89%
4.37%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SALT LAKE CITY